Halozyme Therapeutics Releases Investor Presentation: Sees FY23 EPS $2.77-$2.80 Vs $2.74 Est.; Revenue $827M-$832M Vs $835.69M Est.; FY24 EPS $3.55-$3.90 Vs $3.69 Est.; Revenue $915M-$985M Vs $1.1B Est.
Portfolio Pulse from Benzinga Newsdesk
Halozyme Therapeutics released an investor presentation forecasting FY23 EPS of $2.77-$2.80, slightly above the $2.74 estimate. However, revenue projections of $827M-$832M fall short of the expected $835.69M. For FY24, the company anticipates EPS of $3.55-$3.90, which brackets the $3.69 estimate, but revenue forecasts of $915M-$985M are below the $1.1B estimate.
January 17, 2024 | 5:56 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Halozyme Therapeutics expects FY23 EPS to slightly exceed estimates, with revenues below expectations. FY24 EPS projections are mixed, but revenue forecasts are significantly lower than estimates.
The company's EPS forecast for FY23 is positive, which could support the stock price in the short term. However, the lower revenue projections for both FY23 and FY24 compared to analyst estimates could lead to negative sentiment among investors, potentially causing a short-term decline in the stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100